Project Grant HT94252510784

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $994,859 to Cytoagents Inc. to develop the compound CTO1681 for the prevention and treatment of cytokine release syndrome (CRS) associated with chimeric antigen receptor (CAR) T-cell therapy. Cytoagents is conducting a Phase 1b clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of CTO1681 in reducing CRS and immune effector cell-associated neurotoxicity...

This Project Grant award of $188,169.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), aims to develop a gene therapy vector using the adeno-associated virus (AAV) system for treating Kaposi's sarcoma-associated herpesvirus (KSHV)-associated malignancies. The key objectives are to complete proof-of-concept studies evaluating the biological activity and efficacy of the AAV vector in killing cancer cells through in vitro assays and xenograft mouse models. The...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $686,979 to The Regents of the University of California, San Francisco (UCSF) to develop an integrated metabolic therapy and imaging strategy for diffuse midline gliomas (DMGs), a type of malignant brain tumor in children. The key objectives are to: Investigate how the H3K27M mutation that drives DMG tumorigenesis affects tumor cell metabolism and the tumor microenvironment. Determine...

This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $374,000.00 to the University of California, Los Angeles (UCLA) to develop and evaluate a novel hematopoietic stem cell-based chimeric antigen receptor (CAR) macrophage therapy for Alzheimer's disease (AD). The key objectives are to: 1) Optimize an AB-targeting CAR-macrophage (CAR-M) therapy for in vitro efficacy against AB aggregates and reducing neuroinflammation, and 2) Investigate the safety...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $639,004 to Mayo Clinic from January 1, 2025 to December 31, 2029 to conduct research on using a novel long-acting interleukin-7 (NT-I7) in combination with anti-PD-1 checkpoint blockade for the treatment of glioblastoma. The key products and services to be delivered under this award include: Collecting and processing pre- and post-treatment tumor tissue and peripheral blood samples...

This $178,909 Project Grant awarded by the National Cancer Institute under the Cancer Treatment Research federal grant program (CFDA 93.395) aims to accelerate the incorporation of immunotherapy and CD30-targeted cellular therapy into the treatment of Hodgkin lymphoma in children, adolescents, and young adults (AYAs). The award supports the principal investigator, Dr. Castellino, in her role as the Scientific Chair of the Hodgkin Lymphoma Committee in the Children's Oncology Group. Key...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Northwestern University provides $577,634 to investigate the role of the SEC61 protein complex in overcoming resistance to immunotherapy in glioblastoma (GBM), an aggressive form of brain cancer. The key objectives are to: 1) understand how SEC61G expression interacts with the MAPK pathway to contribute to T cell-mediated therapeutic resistance in glioma cells; 2) determine the impact of...

The National Cancer Institute (NCI) awarded a $1,335,041 project grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Regents of the University of California, San Francisco (UCSF) on August 7, 2024. The grant aims to develop metabolic therapy and imaging techniques to improve outcomes and quality of life for patients with diffuse midline gliomas (DMGs), a type of devastating brain cancer in children. Specifically, the project will determine if combined inhibition of...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $433,157 to the Northshore University Healthsystem Research Institute to investigate the role of lipid-rich macrophages in the tumor microenvironment of prostate cancer. The primary objectives are to define the mechanisms regulating the immuno-metabolic axis in adipose tissue macrophages and tumor-associated macrophages, and determine whether a metabolically-activated macrophage...

This $1,124,607 Project Grant awarded by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) supports a Phase 2 multi-center clinical trial of a novel CD5 CAR T-cell therapy (MB-105) developed by March Biosciences Inc. for the treatment of relapsed/refractory T-cell lymphoma. The therapy is designed to selectively target and eradicate malignant T-cells while preserving healthy T-cells, addressing a significant unmet need in this aggressive cancer. The 2-year project will...